L-Arginine as a Dietary Supplement and its Role in Management of Sickle Cell Anaemia and Ischemia
Keywords:Sickle Cell Anaemia, L-Arginine, Ischemia, Glutamate, Vasodilation, Nitric Oxide
Now a day’s problem in health has become more common. So, instead of curing them, prevention through dietary supplements has proven to be useful. In the case of patients who have already developed the disease at least relieving pain and suffer is a challenging thing. Arginine reduces the pain associated by synthesizing NO and causing vasodilation of blood vessels in sickle cell anaemia. Ornithine is converted to citrulline and finally to arginine through certain metabolic reactions like transamination. Arginine through NO regulates the endothelium of blood vessels and protects against trauma and ischemia. Arginine supplementation along with antioxidants proved to be useful due to additional protection offered during ischemia.
How to cite this article:
Beeram E. L-Arginine as a Dietary Supplement and its Role in Management of Sickle Cell Anaemia and Ischemia. J Adv Res Food Sci Nutr 2019; 2(1&2): 28-30.
Kato GJ, Zeneng W, Taylor JG VI, et al. Arginine metabolite profiling in sickle cell disease: abnormal levels and correlations with pulmonary hypertension, desaturation, hemolysis and organ dysfunction. Blood 2006; 108: 1205.
Kondoh T, Kameishi M, Mallick HN et al. Lysine and arginine reduce the effects of cerebral ischemic insults and inhibit glutamate-induced neuronal activity in rats. Front Integr Neurosci. 2010; 4(18): 1-10.
Wang Q, Simonyi A, Li W, et al. Dietary grape supplement ameliorates cerebral ischemia-induced neuronal death in gerbils. Mol Nutr Food Res. 2005; 49(5): 443-451.
Fazelian S, Hoseini M, Namazi N, et al. Effects of L-Arginine supplementation on antioxidant status and body composition in obese patients with pre-diabetes: a randomized controlled clinical trial. Adv Pharm Bull. 2014; 4(Suppl 1): 449-454.
McNeal CJ, Meininger CJ, Reddy D, et al. Safety and effectiveness of arginine in adults. J Nutr 2016; 146(12): 2587S-93S.
Jin-Moo L, Grabb MC, Zipfel GJ, et al. Brain tissue responses to ischemia. J Clin Invest 2000; 106(6): 723-731.
Clinical trials (2019 a). Effects of L-arginine supplementation in adults with moderate to severe asthma. Retrieved May 03, 2010. Available from: https://clinicaltrials.gov/ct2/show/NCT00280683.
Clinical trials (2019 b). L-Arginine and antioxidant vitamins during pregnancy to reduce preeclampsia. (L-Arg). Retrieved May 01, 2010. Available from: https://clinicaltrials.gov/ct2/show/NCT00469846.
We, the undersigned, give an undertaking to the following effect with regard to our article entitled
________________________________________________________________________________” submitted for publication in (Journal title)________________________________________________ _______________________________________________________Vol.________, Year _________:-
1. The article mentioned above has not been published or submitted to or accepted for publication in any form, in any other journal.
2. We also vouchsafe that the authorship of this article will not be contested by anyone whose name(s) is/are not listed by us here.
3. I/We declare that I/We contributed significantly towards the research study i.e., (a) conception, design and/or analysis and interpretation of data and to (b) drafting the article or revising it critically for important intellectual content and on (c) final approval of the version to be published.
4. I/We hereby acknowledge ADRs conflict of interest policy requirement to scrupulously avoid direct and indirect conflicts of interest and, accordingly, hereby agree to promptly inform the editor or editor's designee of any business, commercial, or other proprietary support, relationships, or interests that I/We may have which relate directly or indirectly to the subject of the work.
5. I/We also agree to the authorship of the article in the following sequence:-
Authors' Names (in sequence) Signature of Authors
1. _____________________________________ _____________________________________
2. _____________________________________ _____________________________________
3. _____________________________________ _____________________________________
4. _____________________________________ _____________________________________
5. _____________________________________ _____________________________________
6. _____________________________________ _____________________________________
7. _____________________________________ _____________________________________
8. _____________________________________ _____________________________________
(I). All the authors are required to sign independently in this form in the sequence given above. In case an author has left the institution/ country and whose whereabouts are not known, the senior author may sign on his/ her behalf taking the responsibility.
(ii). No addition/ deletion/ or any change in the sequence of the authorship will be permissible at a later stage, without valid reasons and permission of the Editor.
(iii). If the authorship is contested at any stage, the article will be either returned or will not be
processed for publication till the issue is solved.